UCB (OTCMKTS:UCBJF) Reaches New 52-Week High – What’s Next?

UCB SA (OTCMKTS:UCBJF) hit a new 52-week high during mid-day trading on Friday . The stock traded as high as $317.94 and last traded at $317.94, with a volume of 186 shares trading hands. The stock had previously closed at $302.5125.

Analysts Set New Price Targets

UCBJF has been the subject of several analyst reports. Stephens reissued an “overweight” rating on shares of UCB in a research note on Thursday. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of UCB in a report on Monday, December 8th. Finally, Barclays reiterated an “overweight” rating on shares of UCB in a research note on Tuesday, January 6th. Four investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy”.

UCB Trading Up 5.1%

The firm has a 50-day moving average price of $283.99 and a two-hundred day moving average price of $258.40. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.